| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
antimicrobial
Dihydropteroate synthase (DHPS) in the bacterial folate synthesis pathway. Sulfaproxiline is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, an enzyme involved in the synthesis of folic acid. The compound acts as a competitive inhibitor of p-aminobenzoic acid (PABA), a substrate for DHPS. By inhibiting folate synthesis, the compound prevents the production of nucleotides and nucleic acids, leading to bacterial growth inhibition. |
|---|---|
| ln Vitro |
Sulfaproxiline is a sulfonamide antibiotic with antibacterial activity against a range of Gram-positive and Gram-negative bacteria. It acts by inhibiting bacterial dihydropteroate synthase, blocking folate synthesis and bacterial growth. The compound exhibits bacteriostatic activity, inhibiting bacterial growth rather than directly killing bacteria. Its antibacterial spectrum includes various pathogenic bacteria susceptible to sulfonamides. The compound is a member of the sulfa drug class, which includes other antibiotics such as sulfadiazine and sulfamethoxazole.
|
| ln Vivo |
In vivo, Sulfaproxiline acts as a sulfonamide antibiotic with antibacterial activity. It is typically administered orally for the treatment of bacterial infections. The compound is absorbed from the gastrointestinal tract and distributed throughout the body. It is metabolized in the liver and eliminated primarily in the urine. Sulfonamides are used for the treatment of urinary tract infections, respiratory infections, and other bacterial infections.
|
| Enzyme Assay |
In vitro antibacterial susceptibility testing is performed using broth dilution or agar dilution methods according to CLSI or EUCAST guidelines. Bacterial strains (e.g., E. coli, S. aureus) are cultured in Mueller-Hinton broth or agar. Varying concentrations of Sulfaproxiline (0.125-256 μg/mL) are added to the medium. The minimum inhibitory concentration (MIC) is determined as the lowest concentration that inhibits visible bacterial growth after 18-24 hours of incubation at 37°C. For enzyme assays, dihydropteroate synthase inhibition is measured using cell-free bacterial extracts or purified enzyme, with PABA as substrate. Inhibition of enzyme activity is determined by measuring product formation.
|
| Cell Assay |
No specific cell-based assay protocols are documented for Sulfaproxiline. For antibacterial activity testing, bacterial cells (not mammalian cells) are used in susceptibility assays. Bacteria are cultured in appropriate media and treated with varying concentrations of the compound. Bacterial growth is measured by optical density at 600 nm or by colony counting. The compound's bacteriostatic effect is determined by comparing growth in treated vs. untreated cultures. For mechanistic studies, bacterial folate levels or nucleotide synthesis may be measured.
|
| Animal Protocol |
In animal models, Sulfaproxiline is typically administered orally or intraperitoneally to rodents in models of bacterial infection. Animals are infected with pathogenic bacteria and treated with the compound. Efficacy is assessed by bacterial counts in tissues or blood, survival rates, and clinical signs of infection. Pharmacokinetic studies measure drug concentrations in plasma, tissues, and urine. The compound is absorbed from the GI tract and distributed systemically.
|
| ADME/Pharmacokinetics |
Sulfaproxiline is a sulfonamide antibiotic that is typically absorbed from the gastrointestinal tract and distributed throughout the body. It is metabolized in the liver, primarily by acetylation, and eliminated in the urine. The compound's pharmacokinetic properties are similar to other sulfonamides, with variable oral bioavailability depending on the specific compound. The compound should be stored as powder under appropriate conditions.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are documented for Sulfaproxiline. As a sulfonamide antibiotic, it may cause side effects including gastrointestinal disturbances, allergic reactions, and, rarely, hematological effects (agranulocytosis, hemolytic anemia) or hypersensitivity reactions (Stevens-Johnson syndrome). Sulfonamides can also cause crystalluria, which may lead to kidney damage. The compound is contraindicated in patients with sulfonamide allergy, severe renal impairment, or porphyria. Standard safety precautions should be observed when handling the compound. The compound is intended for research use only.
|
| Additional Infomation |
Sulfaproxyline is a sulfonamide antibiotic used to treat urinary tract infections.
Sulfaproxiline is a sulfonamide antibiotic belonging to the sulfa drug class. It acts by inhibiting bacterial dihydropteroate synthase, blocking folate synthesis and bacterial growth. The compound is also known as sulfaproxiline or 4-amino-N-(3-(4-aminobenzenesulfonamido)propyl)benzenesulfonamide. It is used in research on antibacterial agents and bacterial infections. The compound is intended for research use only. |
| Molecular Formula |
C16H18N2O4S
|
|---|---|
| Molecular Weight |
334.3901
|
| Exact Mass |
334.099
|
| Elemental Analysis |
C, 57.47; H, 5.43; N, 8.38; O, 19.14; S, 9.59
|
| CAS # |
116-42-7
|
| PubChem CID |
67002
|
| Appearance |
Solid powder
|
| Density |
1.29g/cm3
|
| Index of Refraction |
1.593
|
| LogP |
4.227
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
23
|
| Complexity |
485
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C1C([H])=C([H])C(=C([H])C=1[H])N([H])[H])(N([H])C(C1C([H])=C([H])C(=C([H])C=1[H])OC([H])(C([H])([H])[H])C([H])([H])[H])=O)(=O)=O
|
| InChi Key |
FBFBRAFXKGRRHI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H18N2O4S/c1-11(2)22-14-7-3-12(4-8-14)16(19)18-23(20,21)15-9-5-13(17)6-10-15/h3-11H,17H2,1-2H3,(H,18,19)
|
| Chemical Name |
Benzamide, N-((4-aminophenyl)sulfonyl)-4-(1-methylethoxy)-
|
| Synonyms |
G 14289; G-14289; G14289;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9905 mL | 14.9526 mL | 29.9052 mL | |
| 5 mM | 0.5981 mL | 2.9905 mL | 5.9810 mL | |
| 10 mM | 0.2991 mL | 1.4953 mL | 2.9905 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
